Virtu Financial’s Biocept, Inc. BIOC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-13,777
| Closed | -$17K | – | 2259 |
|
|
2023
Q3 | $17K | Buy |
+13,777
| New | +$16.6K | ﹤0.01% | 1041 |
|
|
2023
Q1 | – | Sell |
-767
| Closed | -$12K | – | 2395 |
|
|
2022
Q4 | $12K | Buy |
+767
| New | +$16.9K | ﹤0.01% | 1363 |
|
|
2022
Q3 | – | Sell |
-940
| Closed | -$27K | – | 2448 |
|
|
2022
Q2 | $27K | Buy |
+940
| New | +$42.8K | ﹤0.01% | 1276 |
|
|
2021
Q3 | – | Sell |
-633
| Closed | -$80K | – | 2163 |
|
|
2021
Q2 | $80K | Buy |
+633
| New | +$85.7K | 0.01% | 1250 |
|
|
2021
Q1 | – | Sell |
-488
| Closed | -$65K | – | 2203 |
|
|
2020
Q4 | $65K | Buy |
+488
| New | +$69.6K | 0.01% | 1177 |
|
|
2019
Q3 | – | Sell |
-89
| Closed | -$30K | – | 1958 |
|
|
2019
Q2 | $30K | Buy |
89
+39
| +78% | +$12.4K | ﹤0.01% | 1302 |
|
|
2019
Q1 | $17K | Buy |
+50
| New | +$20.3K | ﹤0.01% | 1298 |
|
|
2018
Q3 | – | Sell |
-14
| Closed | -$25K | – | 2372 |
|
|
2018
Q2 | $25K | Buy |
+14
| New | +$28.3K | ﹤0.01% | 1839 |
|
|
2018
Q1 | – | Sell |
-13
| Closed | -$80K | – | 2801 |
|
|
2017
Q4 | $80K | Buy |
13
+9
| +225% | +$71.1K | ﹤0.01% | 1975 |
|
|
2017
Q3 | $39K | Buy |
+4
| New | +$47.4K | ﹤0.01% | 2262 |
|
Virtu Financial's BIOC Position: Q4 2023 in Review
Virtu Financial sold out of Biocept, Inc. (BIOC) in Q4 2023, closing a stake of 13,777 shares — an estimated $17K sold.
Virtu Financial first reported a position in BIOC in Q3 2017 and held it in 10 quarters. The position peaked at $80K in Q2 2021. 0 funds tracked by Wall St. Rank hold BIOC as of Q4 2023.
- Virtu Financial reported no remaining Biocept, Inc. position as of Q4 2023 after selling out during the quarter.
- Virtu Financial sold 13,777 Biocept, Inc. shares in Q4 2023, an estimated $17K.
- Virtu Financial first reported a position in Biocept, Inc. in Q3 2017 and held it in 10 quarters.
- Virtu Financial's Biocept, Inc. position peaked at $80K in Q2 2021.
- 0 funds tracked by Wall St. Rank held Biocept, Inc. as of Q4 2023.
Based on Virtu Financial's 13F filing for Q4 2023, filed 26 Feb 2024.